Brought to you by:
New VOYAGER PAD analysis confirms consistent benefit of low-dose rivaroxaban plus aspirin following lower extremity revascularization
Data from a new prespecified analysis of the phase III VOYAGER PAD clinical trial show that low-dose rivaroxaban plus aspirin resulted in a 33% reduction in acute limb ischemia and a 15% reduction in major adverse limb and cardiovascular events,…
‘Voices of Vascular’ series celebrates Women’s History Month
The contributions of the Society for Vascular Surgery’s women members take center stage this month as part of the SVS Foundation’s “Voices of Vascular” series. The “Voices” series is designed to help celebrate the diversity in the vascular surgery specialty.…
ACC 2023: Large bore mechanical thrombectomy reduces adverse outcomes in high-risk PE patients
Large bore mechanical thrombectomy with the FlowTriever system (Inari Medical) in patients with high-risk pulmonary embolism (PE) was associated with a significantly lower occurrence of meaningful in-hospital adverse clinical outcomes compared to other contemporary treatments, data presented at the American…
Apply for Brandeis health policy program by March 15
Society for Vascular Surgery (SVS) members have until March 15 to apply for a scholarship to attend the Executive Leadership Program in Health Policy and Management at Brandeis University. The week-long program for physicians and surgeons will be June 4–10…
RESCUE trial shows reduction in segmental and main pulmonary artery occlusions
Robert A. Lookstein, MD, who is executive vice chair, Diagnostic, Molecular and Interventional Radiology at the Icahn School of Medicine at Mount Sinai Hospital in New York today presented the results of a subanalysis of Thrombolex’s National Heart, Lung and…
‘SVS Presents’ provides enhanced learning opportunities
The Society for Vascular Surgery (SVS) will debut “SVS Presents” April 12, a monthly webinar series that provides an evening of educational programming for members. “Presents” is in response to a key finding from the 2021 Educational Needs Assessment and…
AVF 2023: Results from first US trial of Sonovein delivered
The 2023 annual meeting of the American Venous Forum (AVF) heard the final results from the first U.S. trial of the emerging varicose vein treatment, Sonovein echotherapy, with data showing a 100% technical feasibility at three months—which was the principal…
The top 10 most popular Vascular Specialist stories of February 2023
In February 2023, the hits with Vascular Specialist readers included positive safety and efficacy findings from the PRESERVE trial; the announcement of the scientific program for Sudan’s first vascular meeting; the release of a former Society for Vascular Surgery (SVS) President’s…
VESS 2023: pMAC score found to be ‘important predictor’ of CLTI revascularization outcomes
Having observed a strong relationship between calcification and subsequent limb loss, a research team led by investigators from the University of California San Francisco (UCSF) have conducted a single-center, retrospective follow-up extending an initial study evaluating pedal medial arterial calcification…
AVF 2023: FLASH registry suggests ‘favorable safety and effectiveness profile’ in high-risk PE patients
Among 61 high-risk pulmonary embolism (PE) patients followed through to the 30-day visit in the U.S. cohort of the FLASH registry, no mortalities were recorded, while at 48 hours post-treatment with the FlowTriever mechanical embolectomy system, likewise, there were no…